Psychedelics for major depression-From controlled research settings into broader clinical use.
Cell Rep Med September 1, 2025 Mihai Avram, Stefan Borgwardt
Psychedelics have shown promising antidepressant effects in recent phase 2 randomized controlled trials, with phase 3 studies underway. While therapeutic outcomes are encouraging, the underlying mechanisms—from receptor-level pharmacology to subjective experience and context—remain only partially understood. We highlight clinical and mechanistic advances and outline priorities for future...